Relationship between Antiphospholipid Antibodies and Major Adverse Cardiovascular Events after Drug-Eluting Stent Implantation in Patients with Acute Myocardial Infarction.
- Author:
Yeoun Su JUNG
1
;
Bong Ryeol LEE
;
Han Jun RYU
;
Min Kyu PARK
;
Min Hee KIM
;
Ho Jin JUNG
;
Jun Young LEE
;
Hyun Jae KANG
;
Byung Chun JUNG
;
Soon Hee CHANG
Author Information
1. Department of Internal Medicine, Daegu Fatima Hospital, Daegu, Korea. brlee120gg@gmail.com
- Publication Type:Original Article
- Keywords:
Antiphospholipid antibody;
Drug-eluting stent;
Acute myocardial infarction
- MeSH:
Antibodies, Anticardiolipin;
Antibodies, Antiphospholipid;
Drug-Eluting Stents;
Follow-Up Studies;
Humans;
Immunoglobulin G;
Immunoglobulin M;
Incidence;
Lupus Coagulation Inhibitor;
Myocardial Infarction;
Prognosis
- From:Korean Journal of Medicine
2013;84(5):681-689
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Several studies have reported an association between antiphospholipid antibodies (APA) and major adverse cardiovascular events (MACE) following acute myocardial infarction (AMI). However, the relationship between APA and the prognosis after drug-eluting stent (DES) implantation in patients with AMI is not known. METHODS: Thus, we investigated the relationship between the incidence of MACE and APA levels in patients with AMI who underwent successful DES implantation. RESULTS: Of 182 patients, 78 (42.9%) tested positive for APA. Lupus anticoagulant was positive in 37.6% (68 of 181) patients, anticardiolipin antibody IgM was positive in 8.3% (15 of 180), and anticardiolipin antibody IgG was positive in 1.7% (3 of 180) patients. At follow up, a MACE had occurred in 11 (14.1%) patients in the APA-positive group and in seven (6.7%) patients in the APA-negative group (p = 0.099). CONCLUSIONS: No significant association was found between the incidence of MACE and the presence of APA in patients with AMI who underwent successful DES implantation.
